Remarkably, recent evidence suggests that the number of copies per milliliter of PD-L1 mRNA in plasma-derived exosomes can be used to assess immunotherapy response and disease progression in melanoma and NSCLC [13]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.